Analysis of Capillary Retinal and Papillary Vascularization in Patients With Amyotrophic Lateral Sclerosis - CAPISLA

  • End date
    Feb 14, 2023
  • participants needed
  • sponsor
    University Hospital, Angers
Updated on 14 October 2021
neurological disorder
primary lateral sclerosis
Accepts healthy volunteers


Amyotrophic Lateral Sclerosis, or Charcot's disease, is a neurodegenerative disease affecting motor neurons. The disease affects between 5 and 10 people per 100,000 in the world, nearly 7,000 patients are affected in France. The only therapeutic treatment available to date in France is riluzole, which slows the progression of the disease. Amyotrophic Lateral Sclerosis is the first degenerative disease affecting motor neurons. However, recent evidence suggests that the impairment extends beyond motor neurons alone.

Optical Coherence Tomography analyzes made it possible to highlight ophthalmologic damage in patients with Amyotrophic Lateral Sclerosis, in particular at the macula and papilla, although some results are contradictory.

No angiographic Optical Coherence Tomography analysis has been performed to date in patients with Amyotrophic Lateral Sclerosis. However, in the hypothesis of microvascular involvement participating in the pathophysiology of neurodegeneration in Amyotrophic Lateral Sclerosis, these examinations could provide relevant clinical and pathophysiological data by studying the retinal microvascularization of patients with the disease.

Condition Spinal Cord Disorders, Myelopathy, Amyotrophic Lateral Sclerosis, Amyotrophic Lateral Sclerosis (ALS), lou gehrig's disease
Treatment angiographic optical coherence tomography
Clinical Study IdentifierNCT04686110
SponsorUniversity Hospital, Angers
Last Modified on14 October 2021


Yes No Not Sure

Inclusion Criteria

Patient Amyotrophic Lateral Sclerosis
Patient diagnosed with bulbar or spinal ALS defined according to El Escorial criteria (probable or certain)
Hospitalized in a day hospital at the Angers University Hospital as part of his usual follow-up
Control subject
Subject not affected by the disease studied and without a history of neurological disease
Subject matched in age and sex to a case (patient)
For all participants
Major upon inclusion
Signature of informed consent to participate in the protocol

Exclusion Criteria

Patient Amyotrophic Lateral Sclerosis and control subject
Simultaneous participation in another intervention protocol with an experimental treatment
Subject unable to express consent
Known ophthalmologic pathology (maculopathy, glaucoma, optic neuropathy, retinopathy whatever the etiology)
Diabetic subject
Cardiovascular history
Inability to perform the ophthalmological examinations of the study
Pregnant, lactating or parturient woman
Subject under duress psychiatric care
Subject to legal protection
Subject not affiliated or not beneficiary of a social security scheme
Clear my responses

How to participate?

Step 1 Connect with a study center
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact



Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider


Browse trials for

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 



Reply by • Private

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note